Share
TRUEinvivo® is pleased to announce that the patent for the DOSEmapper™ TLD bead strings and Automated DOSEmapper™ TLD Reader was granted in the EU on 6th January 2021. The patent number is EP3341754. This reinforces the first patent grant which was in the USA back in January 2020. The company has further patents pending in key large countries which have high numbers of radiotherapy cancer treatment centres.
on PATENTSCOP
on Espacenet
Related Posts
Dr. Shakardokht Jafari presents DOSEmapper™ at IPEM conference after ESTRO, highlighting glass beads' innovation in dosimetry.
Graduate secures vital government backing for innovative cancer treatment, targeting global markets with Sirius Programme.
TRUEinvivo's DOSEmapper™ technology receives enthusiastic feedback from industry leaders at ESTRO37 conference.
Dr. Shakar Jafari discusses Women in Innovation and cancer care on Huffington Post.
